Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president sent a letter pushing drug companies to slash prices.

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

We estimate Pfizer’s valuation to be $32 per share, reflecting a solid nearly 40% upside. At its current price of $23, Pfizer stock trades at just 8 times trailing earnings of $2.91 per share.

| June 9, 2025, at 8:33 a.m. More ... Reuters FILE PHOTO: Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration By Michael Erman ...

While Pfizer CEO Albert Bourla, Ph.D., said he couldn’t reveal many details, he noted that Pfizer is in “very active discussions” around most favored nation drug pricing.

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US ...

Despite rolling back price increases earlier this year, Pfizer CEO Ian Read said the drugmaker will likely go back to "business as normal" for drug price hikes come January, according to MarketWatch.

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Chief Executive Albert Bourla said on Monday.